Mission Therapeutics granted MHRA Clinical Trial Authorisation for MTX325 for the treatment of Parkinson's Disease

Mission Therapeutics United States of America England United Kingdom

Company on track to dose first participant in multi-part, adaptive Phase 1, first-in-human study in healthy volunteers and Parkinson's Disease (PD) patients in the first quarter of 2024CTA comes as Nature Reviews Drug Discovery hails Mission's mitophagy approach as "an appealing disease-modifying therapeutic strategy" for PDis a world leader in discovering and developing novel therapeutics, which promote the removal of dysfunctional mitochondria, promoting cell health and function. Mitochondria are energy producing organelles, which require lifetime quality control through a ubiquitin-mediated clearance mechanism known as mitophagy. In certain situations, such as cellular stress, cell injury, and/or defects of the mitophagy process, the mitochondria can become dysfunctional and damaging to the cell, leading to reduced energy production, oxidative stress, inflammation and potentially cell death. Dysfunctional mitochondria are significant drivers of disease pathophysiology in acute kidney injury (AKI), Parkinson's Disease (PD), heart failure, Duchenne's Muscular Dystrophy, IPF, mitochondrial diseases and Alzheimer's.

USP30 is a deubiquitylating enzyme that constantly removes ubiquitin from mitochondria, providing a potential brake on the clearance of dysfunctional mitochondria. Mission is currently developing two small molecule drugs, MTX652 (peripheral) and MTX325 (targeting the CNS) which, through inhibition of the mitochondrial DUB enzyme USP30, will promote clearance of dysfunctional mitochondria — consequently improving overall cellular health. Mission's USP30 inhibitors MTX652 and MTX325 could potentially be used to treat any disease or condition driven by mitochondrial dysfunction.

Mission is backed by blue chip investors including Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Rosetta Capital.

[i] https://www.nature.com/articles/s41467-023-42876-1
[ii] USP30 inhibition protects dopaminergic neurons (nature.com)

 

View original content:https://www.prnewswire.co.uk/news-releases/mission-therapeutics-granted-mhra-clinical-trial-authorisation-cta-for-mtx325-for-the-treatment-of-parkinsons-disease-302005515.html

@ prnewswire.co.uk